Document:

Exhibit
10.04

 

SETTLEMENT
AGREEMENT AND RELEASE

 

THIS
SETTLEMENT AGREEMENT AND RELEASE (the “Settlement Agreement”), is made and entered into as of this 9th day of
August 2021 by and between: (i) FORTIFIED MANAGEMENT GROUP, LLC (“Fortified”)
and JODY R. SAMUELS (“Samuels”) on the one hand; and CURATIVE BIOTECHNOLOGY, INC. f/k/a CONNECTYX
TECHNOLOGIES HOLDINGS GROUP, INC., on the other hand (“Curative” and together with Fortified and Samuels, the “Parties”).

 

RECITALS

 

WHEREAS,
on May 4, 2021, Fortified and Samuels sued Curative via the suit styled Fortified Management Group, LLC and Jody R. Samuels v. Curative
Biotechnology, Inc. f/k/a Connectyx Technologies Holdings Group, Inc., Case No. 502021CA005665XXXXMB pending in the Circuit Court
of The Fifteenth Judicial Circuit, In And For Miami-Dade County, Florida (the “Lawsuit”); and

 

WHEREAS,
although none of the Parties admit to liability or fault, all are amenable to resolving the disputes related to the Lawsuit.

 

NOW,
THEREFORE, in consideration of the foregoing promises and for other good and valuable consideration, the receipt and sufficiency
of which is hereby acknowledged by the Parties, the Parties agree as follows:

 

	1.	Recitals.
                                            The foregoing Recitals are true and correct and are incorporated by reference herein.

 

	2.	Governing
                                            Law. This Settlement Agreement shall be governed by the laws of the State of Florida,
                                            regardless of Florida’s conflict of laws principles.

 

	3.	Purpose.
                                            The Parties agree that the purposes of this Settlement Agreement are to: (i) conclusively,
                                            fully, and finally resolve the Lawsuit and any other currently existing claims or disputes
                                            between Curative, on the one hand, and either Fortified or Samuels on the other, and; (ii)
                                            irrevocably extinguish, relinquish, surrender, and completely abandon any and all right,
                                            title and interest (contingent or otherwise) that either Fortified, Samuels, their affiliates,
                                            or assignees have in that certain Convertible Promissory Note dated April 23, 2013
                                            in the principal amount of Ninety Seven Thousand Five Hundred Dollars ($97,500.00), a copy
                                            of which is attached hereto and incorporated by reference hereby as Exhibit A (the
                                            “Note”).

 

	4.	Effective
                                            Date. The “Effective Date” shall be the latest of following events (i) the
                                            date the final party executes this Settlement Agreement and (ii) the date Mark Migdal &
                                            Hayden c/o Yaniv Adar, Esq., 80 S.W. 8th Street, Suite 1999, Miami, Florida 33130 (“Mark
                                            Migdal”) provides a W9 and wire instructions to its trust account to Curative.

 

	5.	The
                                            Note and Assignments. On the Effective Date, Fortified and Samuels shall deliver a lost
                                            note affidavit in the form attached hereto as Exhibit B (the “Lost Note Affidavit”)
                                            to Rennert Vogel Mandler & Rodriguez, P.A., c/o Thomas S. Ward, Esq., 100 S.E. Second
                                            Street, Suite 2900, Miami, Florida 33131 (“Rennert Vogel”).

 

    	 

    	Settlement Agreement and Release
	Page 2 of 13

    

 

	6.	The
                                            Settlement Payment. As consideration for this settlement, Fortified and Samuels have
                                            agreed to jointly accept $100,000.00 in cash to be divided among them as they deem fit (the
                                            “Settlement Payment”). On the Effective Date—after Rennert Vogel has received
                                            the Lost Note Affidavit—Curative shall pay the Settlement Payment by wire to the Mark
                                            Migdal & Hayden Trust Account c/o Yaniv Adar, Esq., 80 S.W. 8th Street, Suite 1999,
                                            Miami, Florida 33130 (“Mark Migdal”).

 

	7.	(i)
                                            The Settlement Shares. Also as consideration for this settlement, Fortified and Samuels
                                            have agreed to jointly accept 2,000,000 restricted shares of Curative’s Common Stock,
                                            which have piggyback registration rights, as set forth below. On the Effective Date—after
                                            Rennert Vogel has received the Lost Note Affidavit—Curative shall forthwith deliver
                                            to its transfer agent a written instruction to deliver to Fortified and Samuels: (i) one
                                            (1) certificate i/n/o Fortified Management Group, LLC, evidencing ownership of 1,700,000
                                            shares of Common Stock, par value $0.0001 per share, of Curative (the “Fortified
                                            Shares”); and (ii) one (1) certificate i/n/o Jody Samuels, evidencing ownership
                                            of 300,000 shares of Common Stock, par value $0.0001 per share, of Curative (the “Samuels
                                            Shares,” and together with the Fortified Shares, the “Settlement Shares”).
                                            The transfer agent should be directed to deliver the Fortified Shares to Fortified c/o Thomas
                                            Scipione at 135 El Camino Loop, Staten Island, New York 10309. The transfer agent should
                                            be directed to deliver the Samuels Shares to Samuels at 121 Wilson Terrace, Staten Island,
                                            New York 10304.

 

The
Settlement Shares are “restricted securities” as such term is defined under the Securities Act of 1933, as amended (the “Securities
Act”) and all certificates evidencing the Settlement Shares shall bear the following legend:

 

THE
SECURITIES EVIDENCED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”)
AND MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES
ACT COVERING THE TRANSFER OR PURSUANT TO AN EXEMPTION FROM REGISTRATION OR AN OPINON OF COUNSEL SATISFACTORY TO THE COMPANY THAT SUCH
REGISTRATION IS NOT REQUIRED.

 

(ii)
Piggyback Registrations.

 

(a)
Piggyback Registrations. Curative will notify Fortified and Samuels (each a “Holder” and together the “Holders”)
in writing at least thirty (30) days prior to filing any registration statement under the Securities Act for purposes of effecting a
public offering of securities of Curative (including, but not limited to, registration statements relating to secondary offerings of
securities of Curative and selling securityholder resale registration statement, but excluding a Registration Statement on Form S-4 or
S-8 or any successor form) and will afford each such Holder an opportunity to include in such registration statement all or any part
of the Settlement Shares (also referenced herein as the “Registrable Securities”) then held by such Holder. Each Holder
desiring to include in any such registration statement all or any part of the Registrable Securities held by such Holder will, within
twenty (20) days after receipt of the above- described notice from Curative, so notify Curative in writing, and in such notice will inform
Curative of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not
to include all of its Registrable Securities in any registration statement thereafter filed by Curative, such Holder will nevertheless
continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements
as may be filed by Curative with respect to offerings of its securities, all upon the terms and conditions set forth herein.

 

    	 

    	Settlement Agreement and Release
	Page 3 of 13

    

 

(b)
Underwriting. If a registration statement under which Curative gives notice under this Section 7(ii) is for an underwritten
offering, then Curative will so advise the Holders of Registrable Securities. In such event, the right of any such Holder’s Registrable
Securities to be included in a registration pursuant to this Section 7(ii) will be conditioned upon such Holder’s participation
in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.
All Holders proposing to distribute their Registrable Securities through such underwriting will enter into an underwriting agreement
in customary form with the managing underwriter or underwriter(s) selected for such underwriting. Notwithstanding any other provision
of this Agreement, if the managing underwriter(s) determine(s) in good faith that marketing factors require a limitation of the number
of shares to be underwritten, then the managing underwriter(s) may exclude shares (including Registrable Securities) from the registration
and the underwriting, and the number of shares that may be included in the registration and the underwriting will be allocated, first,
to Curative, and second, to each of the Holders requesting inclusion of their Registrable Securities in such registration statement on
a pro rata basis based on the total number of Registrable Securities then held by each such Holder. If any Holder disapproves of the
terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to Curative and the underwriter, delivered
at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn
from such underwriting will be excluded and withdrawn from the registration. For any Holder which is a partnership or corporation, the
partners, retired partners and shareholders of such Holder, or the estates and family members of any such partners and retired partners
and any trusts for the benefit of any of the foregoing persons will be deemed to be a single “Holder,” and any pro rata reduction
with respect to such “Holder” will be based upon the aggregate amount of shares carrying registration rights owned by all
entities and individuals included in such “Holder,” as defined in this sentence.

 

(c)
Expenses. All expenses incurred in connection with a registration pursuant to this Section 7(ii) (excluding underwriters’
and brokers’ discounts and commissions), including, without limitation all federal and “blue sky” registration and
qualification fees, printers’ and accounting fees, fees and disbursements of counsel for Curative and the reasonable fees and disbursements
of one (1) counsel for the selling Holder or Holders will be borne by Curative.

 

(iii)
Obligations of Curative. Whenever required to effect the registration of any Registrable Securities under this Agreement, Curative
will, as expeditiously as reasonably possible:

 

(a)
Furnish to the Holders such number of copies of a prospectus, including a preliminary prospectus, in conformity with the requirements
of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable
Securities owned by them that are included in such registration;

 

    	 

    	Settlement Agreement and Release
	Page 4 of 13

    

 

(b)
Use commercially reasonable efforts to register and qualify the securities covered by such registration statement under such other securities
or Blue Sky laws of such jurisdictions as will be reasonably requested by the Holders, provided Curative will not be required in connection
therewith or as a condition thereto to qualify to do business or to file a general consent to service of process in any such states or
jurisdictions;

 

(c)
In the event of any underwritten public offering, enter into and perform its obligations under an underwriting agreement, in usual and
customary form, with the managing underwriter(s) of such offering (it being understood and agreed, as a condition to Curative’s
obligations under this clause (e), each Holder participating in such underwriting will also enter into and perform its obligations under
such an agreement);

 

(d)
Notify each Holder of Registrable Securities covered by such registration statement at any time when a prospectus relating thereto is
required to be delivered under the Securities Act of the happening of any event as a result of which the prospectus included in such
registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required
to be stated therein or necessary to make the statements therein not misleading in the light of the circumstances then existing; and

 

(e)
Furnish, at the request of any Holder requesting registration of Registrable Securities, on the date such Registrable Securities are
delivered to the underwriters for sale, if such securities are being sold through underwriters, or, if such securities are not being
sold through underwriters, on the date the registration statement with respect to such securities becomes effective, (i) an opinion,
dated as of such date, of the counsel representing Curative for the purposes of such registration, in form and substance as is customarily
given to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting
registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities and (ii) a
“comfort” letter dated as of such date, from the independent certified public accountants of Curative, in form and substance
as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably
satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders
requesting registration of Registrable Securities.

 

(iv)
Furnish Information. It will be a condition precedent to the obligations of Curative to take any action pursuant to Section 7(ii)
hereof that the selling Holders will furnish to Curative such information regarding themselves, the Registrable Securities held by them
and the intended method of disposition of such securities as will be required to timely effect the registration of their Registrable
Securities.

 

(v)
Expiration. Notwithstanding anything contained herein, the Holders’ rights under this Section 7(ii), (iii), and (iv) shall
terminate and shall be of no further force and effect on the date the Registerable Securities are available for resale pursuant to an
exemption from registration under the Securities Act.

 

    	 

    	Settlement Agreement and Release
	Page 5 of 13

    

 

	8.	Dismissing
                                            the Lawsuit With Prejudice. On the Effective Date—after Curative has made the Settlement
                                            Payment and delivered written instructions to issue the Settlement Shares— Fortified
                                            and Samuels shall file an unconditional dismissal with prejudice of the Lawsuit, which states
                                            that all parties agree to bear their own respective attorneys’ fees and costs (the
                                            “Dismissal Filing”). Notwithstanding Fortified and Samuels’ filing
                                            of the Dismissal Filing on the Effective Date, Curative agrees that it will owe a one-time
                                            $50,000.00 liquidated damages penalty in favor of Fortified and Samuels jointly (i.e.,
                                            not $50,000.00 for Fortified and another $50,000.00 to Samuels, but rather a single $50,000.00
                                            penalty owed jointly to Fortified and Samuels) if the Settlement Shares are not issued within
                                            72 hours of Curative’s issuing the instructions to the settlement agent.

 

	9.	Releasing
                                            From Trust. Upon Mark Migdal’s filing the Dismissal Filing (i) Mark Migdal shall
                                            be entitled to release from trust the Settlement Payment and deliver it to Fortified and
                                            Samuels and (ii) Rennert Vogel shall be entitled to release from trust the Lost Note Affidavit
                                            and deliver it to Curative.

 

	10.	Attorneys’
                                            Fees and Costs; Exception. The Parties agree to bear their own attorneys’ fees
                                            and costs incurred in connection with the Lawsuit, including those associated with negotiating,
                                            papering, and complying with this Settlement Agreement. The prevailing party in any subsequent
                                            litigation to enforce this Settlement Agreement is entitled to recover its reasonable attorneys’
                                            fees and costs at all levels.

 

	11.	Fortified
                                            and Samuel’s General Release of Curative. Effective immediately upon the filing
                                            of the Dismissal Filing, Samuels and Fortified (and its respective successors, members, officers,
                                            directors, agents, assigns, attorneys, and affiliates) jointly remit, release, acquit and
                                            forever discharge Curative (and its respective successors, members, officers, directors,
                                            agents, assigns, attorneys, and affiliates) from all currently existing claims, counterclaims,
                                            defenses, damages, actions and causes of action, suits, controversies, debts, dues, sums
                                            of money, accounts, specialties, losses, judgments, proceedings, rights, remedies, obligations,
                                            covenants, warranties, representations, contracts, agreements, promises, liabilities, costs,
                                            attorneys’ fees and demands that Samuels and/or Fortified (and its respective successors,
                                            members, officers, directors, agents, assigns, attorneys, and affiliates) have asserted or
                                            could have asserted against Curative (and its respective successors, members, officers, directors,
                                            agents, assigns, attorneys, and affiliates) from the beginning of time through the execution
                                            of this Agreement. This release does not release Curative from performing any obligations
                                            it has to Samuels and Fortified under this Settlement Agreement or any future claims Samuels
                                            or Fortified may have against Curative.

 

    	 

    	Settlement Agreement and Release
	Page 6 of 13

    

 

	12.	Curative’s
                                            General Release of Fortified and Samuels. Effective immediately upon the filing of the
                                            Dismissal Filing, Curative (and its respective successors, members, officers, directors,
                                            agents, assigns, attorneys, and affiliates) jointly remit, release, acquit and forever discharge
                                            Samuels and Fortified (and its respective successors, members, officers, directors, agents,
                                            assigns, attorneys, and affiliates) from all currently existing claims, counterclaims, defenses,
                                            damages, actions and causes of action, suits, controversies, debts, dues, sums of money,
                                            accounts, specialties, losses, judgments, proceedings, rights, remedies, obligations, covenants,
                                            warranties, representations, contracts, agreements, promises, liabilities, costs, attorneys’
                                            fees and demands that Curative (and its respective successors, members, officers, directors,
                                            agents, assigns, attorneys, and affiliates) have asserted or could have asserted against
                                            Samuels and/or Fortified (and its respective successors, members, officers, directors, agents,
                                            assigns, attorneys, and affiliates) from the beginning of time through the execution of this
                                            Agreement. This release does not release Samuels and Fortified from performing any obligations
                                            it has to Curative under this Settlement Agreement or any future claims Curative may have
                                            against Fortified and/or Samuels.

 

	13.	Indemnification.
                                            Fortified and Samuels shall indemnify, hold harmless, and defend Curative (and its respective
                                            successors, members, officers, directors, agents, assigns, attorneys, and affiliates) on
                                            a joint and several basis, of and from and against any losses, action, claim, demand or liability,
                                            including reasonable attorney’s fees and costs, arising from or relating to the Note
                                            and its underlying debt and obligations asserted by any other person or entity.

 

	14.	Legal
                                            Counsel and Additional Representations. The Parties represent and acknowledge that: (i)
                                            they read and write English; (ii) they have all either obtained or had the opportunity to
                                            obtain independent legal counsel before signing this Agreement; (iii) they have all been
                                            fully advised that this Agreement is legally binding on all of them; (iv) there are no representations
                                            or promises made to any of them by the other Party that are not contained in this Settlement
                                            Agreement; (v) all Parties are authorized to sign this Settlement Agreement either on their
                                            own behalf or on behalf of the entity for which they are signing and for all persons, firms
                                            and entities claim by, through or under them; (vi) all corporate action of the undersigned
                                            entities or individuals has been taken to make this Settlement Agreement legal and fully
                                            binding upon all of them; (vii) the only people or entities with any interest in the Note
                                            are Fortified and Samuels; and (viii) neither Fortified nor Samuels have assigned or have
                                            promised to assign any right, title, or interest in the Note to any other person or entity
                                            except the assignment to Samuels as described in the complaint filed in the Lawsuit.

 

	15.	Enforceability.
                                            This Settlement Agreement and its enforceability shall not be affected by the filing of bankruptcy
                                            of any of the Parties or any of their members, shareholders, officers, agents or directors.

 

	16.	Entire
                                            Agreement. This Settlement Agreement contains the entire agreement between the Parties
                                            with respect to the matters addressed herein and no prior representations, inducements, promises,
                                            or agreements, oral or written, between the Parties in respect thereof, shall be of any force
                                            or effect if not expressly embodied in writing herein.

 

	17.	Amendments.
                                            This Settlement Agreement may not be amended or modified except in a writing duly signed
                                            by an authorized representative of all Parties.

 

	18.	Counterparts.
                                            The Parties acknowledge and agree that this Settlement Agreement may be
executed in multiple counterparts, and transmitted via facsimile or e-mail, each such counterpart (whether transmitted via facsimile
or e-mail), when executed, shall constitute an integral part of one and the same Agreement between the parties.

 

    	 

    	Settlement Agreement and Release
	Page 7 of 13

    

 

	19.	Time
                                            of the Essence. Time is of the essence as to all terms of this Settlement Agreement.

 

	20.	Severability.
                                            Without limiting the generality of the foregoing, it is the Parties’ mutual desire
                                            and intention that all provisions of this Settlement Agreement be given full effect and be
                                            enforceable strictly in accordance with their terms. If, however, any part of this Settlement
                                            Agreement is declared to be not enforceable in accordance with its terms or would render
                                            other parts of this Settlement Agreement, in its entirety, unenforceable, the unenforceable
                                            part or parts are to be judicially modified, if at all possible, to come as close as possible
                                            to the expressed intent of such part or parts (and still be enforceable without jeopardy
                                            to other parts of this Settlement Agreement), and then are to be enforced as so modified.
                                            If the unenforceable part or parts cannot be so modified, such part or parts will be unenforceable
                                            and considered null and void in order that the mutual paramount goal (that this Settlement
                                            Agreement is to be enforced to the maximum extent possible strictly in accordance with its
                                            terms) can be achieved.

 

	21.	Further
                                            Assurances. The Parties agree to execute such further and additional documents, instruments
                                            and writings as may be necessary to fully effectuate the terms and provisions of this Settlement
                                            Agreement.

 

	22.	Joint
                                            Preparation of Agreement. This Settlement Agreement shall not be construed against any
                                            of the Parties, but shall be construed as if it were prepared jointly by all Parties, and
                                            any uncertainty or ambiguity, or both, shall not be interpreted against any Party.

 

	23.	Tax
                                            Advice. The Parties understand and agree that their counsel has not provided any tax
                                            or legal advice and has not made any representations regarding tax obligations or consequences,
                                            if any, in connection with this Settlement Agreement. Each Party is responsible for its own
                                            tax consequences that may arise as a result of the execution of this Settlement Agreement.

 

	24.	Confidentiality.
                                            The Parties agree that the terms and conditions of this Settlement Agreement and of the settlement
                                            represented hereby shall be kept strictly confidential and none of the Parties shall make
                                            any statements to third parties regarding the specific terms of this Settlement Agreement,
                                            except: (a) as may be necessary in connection with the Parties’ legal requirements,
                                            including legal, accounting, or securities reporting interests; (b) to enforce the terms
                                            hereof; or (c) as otherwise required by law or court order. The Parties acknowledge and agree
                                            that they have received consideration in exchange for their agreement to this confidentiality
                                            provision. The Parties agree that this confidentiality provision is an important term of
                                            this Settlement Agreement, that any breach of it constitutes a substantial violation of this
                                            Settlement Agreement and that in in addition to any and all other rights and remedies that
                                            may be available to the Parties in respect of such breach, be entitled to equitable relief,
                                            including a temporary restraining order, an injunction, specific performance and any other
                                            relief that may be available from a court of competent jurisdiction (without any requirement
                                            to post bond).

 

    	 

    	Settlement Agreement and Release
	Page 8 of 13

    

 

IN
WITNESS WHEREOF, the Parties have executed this Settlement Agreement as evidenced by the Parties’ signature pages, which follow
forthwith. 

 

[SIGNATURE
PAGES IMMEDIATELY FOLLOW]

 

    	 

    	Settlement Agreement and Release
	Page 9 of 13

    

 

	FORTIFIED
    MANAGEMENT GROUP, LLC	 	 	 
	 	 	 	 	 
	Signature:	/s/
    Thomas Scipione 	 	Date:	August
    9, 2021
	 	 	 	 	 
	Name:	Thomas
    Scipione 	 	 	 
	 	 	 	 	 
	Title:	President	 	 	 
	 	 	 	 	 
	JODY
    R. SAMUELS	 	 	 
	 	 	 	 	 
	Signature:		 	Date:	August
    9. 2021

 

    	 

    	Settlement Agreement and Release
	Page 10 of 13

    

 

Jody
Signature P...

 

	FORTIFll:0
                                            MANAGEMENT GROUP, LLC

	 	 	 
	 	 	 	 	 
	Signature:	 	 	Date:	August
    19 2021
	 	 	 	 	 
	Name:	Thomas
    Scipione	 	 	 
	 	 	 	 	 
	Title:	President	 	 	 
	 	 	 	 	 
	JODY
    R. SAMUELS	 	 	 
	 	 	 	 	 
	Signature:		 	Date:	August
    19 2021

 

    	 

    	Settlement Agreement and Release
	Page 11 of 13

    

 

CURATIVE
BIOTECHNOLOGY, INC. f/k/a CONNECTYX TECHNOLOGIES HOLDINGS GROUP, INC.

 

	Signature:	 /s/ Richard Garr 		Date:	August
    9, 2021
	 	 	 	 	 
	Name:	I.
    Richard Garr	 	 	 
	 	 	 	 	 
	Title:	CEO	 	 	 

 

    	 

    	Settlement Agreement and Release
	Page 12 of 13

    

 

	AGREED
    AND ACKNOWLEDGED:	 	 	 
	 	 	 	 
	RENNERT
    VOGEL MANDLER & RODRIGUEZ, P.A.	 	 	 
	 	 	 	 	 
	Signature:		 	Date:	August
    9, 2021
	 	 	 	 	 
	Name:	Thomas
    S. Ward, Esg.	 	 	 
	 	 	 	 	 
	MARK
    MIGDAL & HAYDEN, P.A.	 	 	 
	 	 	 	 	 
	Signature:		 	Date:	August
    9, 2021
	 	 	 	 	 
	Name:	Yaniv
    Adar, Esq.	 	 	 

 

    	 

    	Settlement Agreement and Release
	Page 13 of 13

    

 

	AGREED
    AND ACKNOWLEDGED:	 	 	 
	 	 	 	 
	RENNERT
    VOGEL MANDLER & RODRIGUEZ, P.A.	 	 	 
	 	 	 	 	 
	Signature:		 	Date:	August
    9, 2021
	 	 	 	 	 
	Name:	Thomas
    S. Ward, Esq. 	 	 	 
	 	 	 	 	 
	MARK
    MIGDAL & HAYDEN, P.A.	 	 	 
	 	 	 	 
	Signature:	 	 	Date:	August
    9, 2021
	 	 	 	 	 
	Name:	Yaniv
    Adar, Esq.Exhibit
10.05

 

 

Sohn
Health Strategies

SPECIAL
ADVISOR TO THE BOARD OF DIRECTORS AND THE CEO AGREEMENT

 

THIS
AGREEMENT is made and entered into effective as of SEPTEMBER 27, 2021, (the “Effective Date”), by and between Curative Biotechnology
Inc., a Florida corporation (the “Company”) with its principal place of business located at 1825 NW Corporate Blvd #110 Boca
Raton, Florida , and Sohn Health Strategies LLC, a New Jersey limited liability company (“Advisor”) with a principal place
of business at 5 Hidden Acres Drive, Voorhees, NJ 08043.

 

1)
Term

 

This
Agreement shall continue for a period of two (2) years from the Effective Date. It may be renewed for a successive one-year term upon
30 days’ notice prior to the scheduled date of termination under mutually agreeable terms.

 

2)
Position and Responsibilities

 

a)
Position. The Board of Directors hereby appoints the Advisor to serve as a special advisor to the Board and the CEO for her term
or until her earlier resignation, removal or death. The advisor shall perform such duties and responsibilities in accordance with Company’s
bylaws and applicable law, and as described below. Advisor hereby agrees to use commercially reasonable efforts to provide the Services.
Advisor shall comply with the statutes, rules, regulations and orders of any governmental or quasi-governmental authority, which are
applicable to the Company and the performance of the Services, and Company’s rules, regulations, and practices as they may from
time-to-time be adopted or modified.

 

Duties:

 

Monthly:
one day review sessions with CEO

 

Quarterly:
Time to prep for two Joint Steering Committee (“JSC”) meetings (objectives to be pre-agreed with CEO, assist CEO to prepare
agenda for distribution to all JSC members)

 

Chair
and participate in the infectious disease (“ID”) Joint Steering Committee meetingand the National EYE Institute (“NEI”)
Joint Steering Committee meeting (or upon the request of the Company, serve as one of Company’s representatives at such meetings)

 

Quarterly:
Attend and prepare minutes for both ID and NEI Joint Steering Committee Meetings

 

Attend
key scientific meetings as a representative of the Company, as requested/approved by CEO and agreed with Advisor.
Ad Hoc availability for calls with CEO, Chairman, other advisors, and NIH investigators on a reasonable schedule agreed with Advisor.

 

    	1

     

    

 

b)
No Conflict. Advisor will not engage in any activity that creates an actual or perceived conflict of interest with Company without
the Company’s consent such consent not to be unreasonably withheld.

 

3)
Compensation

 

a)
Advisor’s Fee. In consideration of the services to be rendered under this Agreement, Company shall pay Advisor with an issuance
on each annual anniversary of the Effective Date during the term of this Agreement 250,000 shares of unregistered common stock of the
Company (the “Common Stock”), with appropriate legend with a basis of eleven cents/share, the closing price of the stock
on the effective date of this agreement. In addition, the Company shall make a one-time grant to the Advisor of stock options at eleven
cents/share, the number of options equal to 1% of the issued and outstanding capital stock of the Company on a fully-diluted basis as
of the Effective Date. The parties agree and acknowledge that a reverse split is likely prior to an anticipated “uplisting”
of the Company’s stock to an exchange, accompanying a capital raise of at least $5,000,000 (the “Capital Raise”); and
that after such reverse split and Capital Raise, the Company shall issue to Advisor a sufficient number of stock options of Common Stock
required to restore Advisor’s stock ownership to the nuber options equaling 1% of issued and outstanding capital stock of the Company
on a fully-diluted basis. The initial 1% equity stake shall vest in two equal parts; 50% upon execution of this Agreement and 50% upon
the first annual anniversary of the Effective Date. Shares issued in connection with any “uplisting” or capital raise shall
vest immediately.

 

b)
In addition, Advisor shall be paid $250,000 per year in cash as a consulting fee, to be paid monthly or quarterly at Advisor’s
discretion. The Company shall begin making the cash payment on the first business day after the Capital Raise has been completed.
Any amount “accrued” between the Effective Date and the completion of the raise shall be prorated and paid monthly over the
remaining months of the first year of the Agreement.

 

c)
All vestings subsequent to the initial vesting are contingent upon this Agreement still being in effect at the time. Notwithstanding
the foregoing, if the Advisor terminates this Agreement for “good reason” as generally understood in the industry, or the
Company terminates this Agreement without “cause” as generally understood in the industry, all as yet unvested stock compensation
shall immediately become vested.

 

d)
Expenses. The Company shall reimburse Director for all reasonable business expenses incurred in the performance of the Services
in accordance with Company’s expense reimbursement guidelines, including necessary or requested travel expenses. Company shall
reimburse Advisor for such travel on business class, or first class if business class is not available.

 

 

    	2

     

    

 

e)
Indemnification. Company will indemnify and defend Advisor and hold Advisor harmless from and against any liability incurred in
the performance of the Services to the fullest extent permitted by applicable law. Further, Company shall indemnify and defend Advisor
and hold Advisor harmless from and against any third-party claims arising from any source whatsoever.

 

f)
Insurance. During the term of this Agreement and for a period of six years thereafter, Company shall, at its own expense, maintain and
carry such types of insurance with financially sound and reputable insurers, in full force and effect that includes, but is not limited
to, commercial general liability in an amount as is consistent with industry norms and is otherwise reasonable for a company in a development
phase similar to that of the Company. Upon Advisor’s request, Company shall provide Advisor with a certificate of insurance from
Company’s insurer evidencing the insurance coverage specified in this Agreement. The certificate of insurance shall name Advisor
as an additional insured. Company shall provide Advisor with at least 30 days’ advance written notice in the event of a cancellation
or material change in Company’s insurance policy. Except where prohibited by law, Company shall require its insurer to waive all
rights of subrogation against Advisor’s insurers and Advisor.

 

4)
Termination

 

a)
Right to Terminate. At any time, Advisor may be removed “for cause” and only for cause; as it is reasonably understood
in the industry. Such termination for cause would end all Company obligations for further Compensation under the Agreement but would
have no effect on vested or paid compensation or upon expenses incurred but not yet reimbursed.

 

b)
Voluntary Termination . Upon voluntary termination via resignation of Advisor prior to the completion of the term of the Agreement
this agreement will terminate. In such case Company shall pay to Advisor all compensation and expenses to which Advisor is entitled up
through the date of termination; and Advisor shall be entitled to its rights under any other applicable law. Thereafter, all of Company’s
obligations under this Agreement shall cease.

 

c)
Survival’ Notwithstanding anything to the contrary set forth in this Agreement, the provisions in the third sentence of
Paragraph 3(a), the last sentence of Paragraph 3(b) and all of Paragraphs 3(c), (d) (as to as yet unreimbursed amounts), (e) and (f)
shall survive expiration or termination of this Agreement. Paragraph 5 shall survive any such expiration or termination for a period
of three years.

 

 

    	3

     

    

 

5)
Nondisclosure Obligations

 

Advisor
shall maintain in confidence and shall not, directly or indirectly, disclose or use, either during or after the term of this Agreement,
any Proprietary Information (as defined below), confidential information, or trade secrets belonging to Company, whether or not it is
in written or permanent form, except to the extent necessary to perform the Services, as required by a lawful government order or subpoena,
or as authorized in writing by Company. “Proprietary Information” means all information pertaining in any manner to the business
of Company, unless (i) the information is or becomes publicly known through lawful means; (ii) the information was part of Advisor’s
general knowledge prior to its relationship with Company; or (iii) the information is disclosed to Advisor without restriction by a third
party who rightfully possesses the information and, This Agreement constitut)es the entire understanding between the parties hereto superseding
all prior and contemporaneous agreements or understandings among the parties hereto concerning the Agreement. to the knowledge of Advisor,
did not learn of it from Company.

 

6)
Entire Agreement

 

This
Agreement constitutes the entire understanding between the parties hereto superseding all prior and contemporaneous agreements or understandings
among the parties hereto concerning the Agreement.

 

7)
Amendments; Waivers

 

This
Agreement may be amended, modified, superseded or canceled, and any of the terms, covenants, representations, warranties or conditions
hereof may be waived, only by a written instrument executed by the parties or, in the case of a waiver, by the party to be charged. Any
amendment or waiver by the Company must be approved by the Company’s Board of Directors and executed on behalf of the Company by
its Chief Executive Officer.

 

8)
Assignment

 

This
Agreement shall not be assignable by Advisor without Company’s consent at Company’s total discretion.

 

9)
Severability

 

If
any provision of this Agreement shall be held by a court to be invalid, unenforceable, or void, such provision shall be enforced to fullest
extent permitted by law, and the remainder of this Agreement shall remain in full force and effect. In the event that the time period
or scope of any provision is declared by a court of competent jurisdiction to exceed the maximum time period or scope that such court
deems enforceable, then such court shall reduce the time period or scope to the maximum time period or scope permitted by law.

 

10)
Governing Law

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of Delaware.

 

 

    	4

     

    

 

11)
Interpretation

 

This
Agreement shall be construed as a whole, according to its fair meaning, and not in favor of or against any party. Captions are used for
reference purposes only and should be ignored in the interpretation of the Agreement.

 

12)
Binding Agreement

 

Each
party represents and warrants to the other that the person(s) signing this Agreement below has authority to bind the party to this Agreement
and that this Agreement will legally bind both Company and Advisor. To the extent that the practices, policies, or procedures of Company,
now or in the future, are inconsistent with the terms of this Agreement, the provisions of this Agreement shall control. Any subsequent
mutually agreed change in Advisor’s duties or compensation will not affect the validity or scope of the remainder of this Agreement.

 

13)
Advisor Acknowledgment

 

Advisor
acknowledges Advisor has had the opportunity to consult legal counsel concerning this Agreement, that Advisor has read and understands
the Agreement, that Advisor is fully aware of its legal effect, and that Advisor has entered into it freely based on its own judgment
and not on any representations or promises other than those contained in this Agreement.

 

14)
Counterparts

 

This
Agreement may be executed in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute
one and the same instrument.

 

15)
Date of Agreement

 

The
parties have duly executed this Agreement as of the Effective Date.

 

	Curative
    Biotechnology Inc.	 	Sohn
    Health Strategies LLC
	 	 	 	 	 
	By:
    	 /s/
    Richard Garr. 	 	By:	 /s Catherine Sohn. 
	 	I Richard Garr, CEO	 	Catherine
    Angell Sohn, Pharm.D., President
	 	1825 NW Corporate Blvd #110	 	[Address]
    
	 	Boca Raton, FL 33431	 	Cell:
    [*] |
	 	 	 	Office:
    [*]

 

 

    	5

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00348-of-00352.parquet"}]]